Compare Citius Pharmaceuticals Inc (CTXR) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Toronto-Dominion Bank — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Toronto-Dominion Bank trades at $113.21 (market cap $185.79B). The key difference: Toronto-Dominion Bank is far larger — about 13641× Citius Pharmaceuticals Inc's market cap, and Toronto-Dominion Bank pays a 2.84% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Toronto-Dominion Bank for 84 Days on average.
| CTXR | TD | |
|---|---|---|
Market Cap | $13.62M | $185.79B |
Volume | 132,438 | 3,263,867 |
Sector | Health | Financials |
52-Week High | $1.82 | $124.80 |
52-Week Low | $0.48 | $78.32 |
Typical Hold Time | 16 Days | 84 Days |
Enterprise Value | $3.79M | $559.06B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
TD stock trades at $113.87, down 3.65% on the day, with technical indicators showing bearish momentum. The company reported strong earnings beats in recent quarters with Q2 2026 EPS of $1.98 beating expectations of $1.74. Revenue growth continues with 2025 revenue reaching $61.28B, though cash flow volatility remains a concern with operating cash flow turning negative in 2025. The $10 billion share buyback program and $108 billion Canadian infrastructure commitment signal management confidence.
TD presents a mixed investment case with solid fundamentals offset by technical weakness. The stock offers value with a reasonable P/E of 17.36 and strong analyst support (52.94% buy ratings), but faces headwinds from cash flow volatility and declining profit margins. The current price near support levels may offer entry points for long-term investors attracted to the dividend yield and buyback program.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
